Peptonic Medical (publ) (“Peptonic”) is expanding its portfolio of clinically proven intimate self-care products with the launch of VagiVital Active Glide, a water-based lubricant specifically designed to enhance intimate experiences while providing deep hydration. This strategic addition to Peptonic’s growing product portfolio addresses the rising demand for lubricants that combine pleasure with care. In 2022, the global market for personal lubricants was valued at approximately USD 1.2 billion and is expected to experience continued strong growth in the coming years.
The personal lubricant market, valued at USD 1.2 billion in 2022, is expected to experience strong growth, driven by increasing awareness of sexual health, rising demand for products that enhance intimacy, and greater acceptance of their use. Women represent a particularly important target group, as lubricant usage is increasing both to enhance intimate experiences and to meet moisturizing and caring needs.
“We are very proud to launch a lubricant that has been carefully designed to meet the specific needs and preferences of women. VagiVital Active Glide will be available in the Nordic markets starting in November, with a gradual introduction in selected international markets in collaboration with our partners,” says Anna Linton, CEO of Peptonic
VagiVital Active Glide is a fragrance-free, water-based lubricant specifically formulated to enhance intimate moments and provide deep hydration without causing irritation. The lubricant is based on Peptonic’s clinically proven gel base, ActiveGel, known for its moisturizing and caring properties
For further information, please contact:
Anna Linton, CEO Peptonic Medical AB
Email: anna.linton@peptonicmedical.se
Phone: +46 70-244 92 07
About Peptonic
PEPTONIC medical AB (publ) is a cutting-edge Swedish biomedical company, dedicated in the development and distribution of clinically proven self-care treatments and self-diagnostic tests in intimate women’s health. The portfolio is sold under the brands Vagivital and Vernivia.
The company’s vision is to revolutionize intimate health by empowering women to diagnose, treat, and prevent intimate medical conditions independently and effectively. Intimate health shall be natural, safe, and easy for women to manage on their own.
Central to Peptonic’s growth strategy is the geographical expansion of VagiVital and Vernivia through local partners. Peptonic Medical also intends to continuously broaden its product portfolio through acquisitions and the development of innovative and competitive products in-house. The company’s mousse-based drug delivery technology, Venerol, and the gel base in VagiVital create favorable conditions for expanding the portfolio.
The company is headquartered in Stockholm, Sweden, and has subsidiaries Common Sense Marketing Inc in the USA and Peptonic Medical Ltd in Israel. Peptonic Medical was founded in 2009, and the company’s shares have been listed on the Spotlight Stock Market since 2014.
